Navigation Links
Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
Date:11/25/2008

clear path for the resubmission of our NDA for NEBIDO(R), our commercial products are performing extremely well in their respective markets, our late stage development programs for octreotide and pagoclone are in full gear, and our successful $105 million financing this summer gives us a strong balance sheet.

"After receiving an Approvable letter in June from the FDA on our NDA for NEBIDO, we began planning the course toward resubmission to address FDA's concerns about the quantification of the incidence of serious cough reactions in clinical trials. The NDA contained a single, serious cough reaction in approximately 4,000 injections of NEBIDO. In September, we reached agreement with FDA that submitting additional safety data from ongoing clinical trials in Europe would be appropriate and sufficient to address their concerns. The new data include the results from approximately 10,000 additional injections in Phase IV trials conducted by our partner, Bayer Schering Pharma AG, Germany. The data from these trials has been collected and we believe that there have been no additional cases of serious cough reaction implying an incidence of approximately 1 in 14,000 injections which we believe confirms the rarity of the adverse event. We expect to re-file the NDA by the end of the first calendar quarter of 2009, and FDA will have six months to review the NDA.

"We continue to see strong performance and positive trends for VANTAS(R) (prostate cancer) and SUPPRELIN(R) LA (central precocious puberty). Sales of VANTAS units in the fourth quarter were up 70% over the fourth quarter last year, and we are encouraged by the trends in the first quarter. VANTAS is the only once-yearly treatment in the market and our sales force has done a terrific job of demonstrating the benefits of a long acting product," continued Dr. Cooper.

"Adoption of SUPPRELIN LA in the treatment of central precocious puberty continues
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Allergan as New Partner for SANCTURA Brand
3. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
4. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
5. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
6. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
7. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
8. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
9. Indevus Announces Management Changes
10. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
11. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Global Stem Cells Group subsidiary Adimarket ... biologic products for the regeneration and repair of human organs ... Cells Group’s ambitious expansion plans in Latin America, a commitment ... regenerative medicine and stem cell therapies. , Bioquark ... have the ability to alter the regulatory state of human ...
(Date:6/2/2015)... June 02, 2015 Research and Markets( http://www.researchandmarkets.com/research/2b7734/molecular ... Diagnostics - Global Market Size, Strategy and Forecasts - ... "Molecular Diagnostics - Global Market Size, Strategy and ... and planners can use. Hundreds of pages of information ... Medicare Fee Payment Schedules to help understand test pricing ...
(Date:6/2/2015)... , June 02, 2015 Research and Markets( ... "Genotyping Market by Technology, Application & by Products - ... The global genotyping market is expected to ... 2015, at a CAGR of 22.3% during the forecast ... will be attributed to the availability of a range ...
(Date:6/2/2015)... 2, 2015   Y-Prime, Inc ., announced ... Exhibition 2015 in Philadelphia , ... biotechnology gathering, allows influential decision makers from the ... can evaluate emerging technologies such as YPrime. ... the design, implementation and management of Interactive Response ...
Breaking Biology Technology:Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 2Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 3Global Molecular Diagnostics Report 2015-2019 - Market Size, Strategy and Forecasts 2Global Molecular Diagnostics Report 2015-2019 - Market Size, Strategy and Forecasts 3Genotyping Market Report 2015 by Technology, Application & by Products - Global Forecast to 2020 for the $17 Billion Market 2YPrime at BIO Exhibition in Philadelphia and DIA in Washington DC during the month of June 2
... 20 At a meeting of the Board,of Directors of ... of fifty cents($0.50) per share on the outstanding shares of ... of record at the close of business,on December 12, 2008. ... of the world,s largest research-driven pharmaceutical and,health care products companies. ...
... 20 Sigma-Aldrich (Nasdaq: SIAL ),announced today ... iScale,Oligos(TM) siRNA. MISSION(R) In VIVO QUALITY and iScale Oligos(TM) ... next step in their RNAi,research with the highest purity ... These siRNA are believed to be well suited to ...
... Nephros, Inc. (Amex: NEP ), a medical device company developing and marketing ... on its operations and strategy. , , Recent ... , Appointed James Scibetta Chairman of ... III President and CEO , Submitted 510k for ...
Cached Biology Technology:Sigma-Aldrich Introduces MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, a Superior Quality siRNA Designed for RNAi Research in Animal Models 2Nephros Provides Corporate Update 2Nephros Provides Corporate Update 3Nephros Provides Corporate Update 4Nephros Provides Corporate Update 5Nephros Provides Corporate Update 6Nephros Provides Corporate Update 7
(Date:4/20/2015)... 20, 2015 Huntington Memorial Hospital is the ... a new miniaturized, wireless monitoring sensor to manage heart ... and only FDA-approved heart failure monitoring device that has ... by physicians to manage heart failure. The ... in the pulmonary artery (PA) during a non-surgical procedure ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/13/2015)... a leading cloud-based consumer engagement platform that provides trusted ... communities around health and wellness, announced today the launching ... The ... vehicle to receive validated health information from consumers. ... will allow higi,s trusted partners, on a user opt-in ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... a class of small molecules known as microRNA have been ... in most animal and plant species. A new study now ... a hallmark of alcohol abuse and dependence. Researchers supported by ... the findings in the July 31 issue of the journal ...
... July 29, 2008 Two Fortune 500 oil companies ... Engineering at the University of Houston. The funds, from ... Corp., will provide support for a new undergraduate program ... by the Texas Higher Education Coordinating Board this fall. ...
... or cold is not only uncomfortable, it can be ... many years now, scientists have understood the molecular mechanisms ... extremely high temperatures that directly trigger heat sensor proteins ... understood is how animals sense very small temperature differences ...
Cached Biology News:MicroRNA implicated as molecular factor in alcohol tolerance 2Energy industry leaders commit $1.6M to UH petroleum program 2Energy industry leaders commit $1.6M to UH petroleum program 3Summer heat too hot for you? What is comfortable? 2Summer heat too hot for you? What is comfortable? 3